Camptothecin-d5

• UNSPSC Description:

  Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].

• Target Antigen:

  ADC Cytotoxin; Antibiotic; Apoptosis; Fungal; Influenza Virus; MicroRNA; Topoisomerase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Epigenetics

• Field of Research:

  Cancer; Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C([2H])([2H])C([2H])([2H])[C@@]1(C2=C(COC1=O)C(N3C(C4=NC5=CC=CC=C5C=C4C3)=C2)=O)O

• Molecular Weight:

  353.38

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Luzzio MJ, et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I.|[3]Bertozzi D, et al. The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells. Mol Cancer Ther. 2014;13(1):239-248.|[4]Schön M, et al. KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst. 2008;100(12):862-875..|[5]Huang Q, et al. Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents. Eur J Med Chem. 2013;63:746-757.|[6]Tesauro C, et al. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study. BMC Cancer. 2019;19(1):1158. Published 2019 Nov 29.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  1329616-37-6